Geniculate Artery Embolization for Knee Osteoarthritis

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

October 26, 2023

Study Completion Date

October 26, 2023

Conditions
Knee Osteoarthritis
Interventions
DEVICE

Gel-Bead embolization

OptiSphere is FDA approved for the embolization of hypervascular tumors. The product is crosslinked with glutaraldehyde, which improves the mechanical strength of the spheres and provides controlled degradation after implant. The spherical shape provides smooth embolic delivery and even, predictable distribution. In this study the Optispheres will be used for Geniculate artery embolization (GAE) which is a minimally-invasive procedure that has historically been performed for treatment of patients with recurrent knee hemarthrosis. Embolization is a procedure in which material is used to block small blood vessels. Angiogenesis, or growth of new vessels, has been implicated in the initiation and maintenance of joint inflammation. GAE has been applied to patients with moderate osteoarthritis-related pain refractory to maximal medical management with preliminary studies demonstrating a reduction in patient pain.

Trial Locations (1)

15232

UPMC Shadyside, Pittsburgh

All Listed Sponsors
lead

Anish Ghodadra

OTHER

NCT04951479 - Geniculate Artery Embolization for Knee Osteoarthritis | Biotech Hunter | Biotech Hunter